Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With Irinotecan in Recurrent SCLC
NCT03651219Phase 3Unknown
- Sponsor
- Beijing Chest Hospital
- Start
- Sep 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of Rivoceranib in small cell lung cancer (SCLC) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoints: Objective Response Rate, Disease Control Rate and 2 more. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03651219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651219.